![]() But the remaining 80 percent of patients were never offered such treatment in the first place. ![]() Their analysis in the CDC’s Morbidity and Mortality Weekly Report found that 20 percent of those patients turned down the drugs when they were offered. They focused on 110 patients who received organ transplants or had other medical conditions such as chronic lymphocytic leukemia that were likely to leave them immunocompromised and thus at greater risk from COVID-19 despite being vaccinated. Researchers from the VA Boston Cooperative Studies Program delved into records from the Veterans Health Administration to look more closely at what happened to high-risk patients who never got Paxlovid, remdesivir or molnupiravir. Centers for Disease Control and Prevention, suggest that some vulnerable patients were not offered the prescription medicines at all, and that doctors need more education to make sure the drugs get to patients who could benefit. Their new findings, published Thursday by the U.S. In Boston, a group of researchers wanted to know why - and what could be done about it. Yet the drugs have remained underused, studies have found. As the toll from the COVID-19 pandemic continued to mount, antiviral medications such as Paxlovid were hailed by health officials as an important way to reduce the risk of severe illness or death.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |